- Home
- EGHT vs CLLS Comparison
EGHT vs CLLS Comparison
Compare EGHT & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EGHT
- CLLS
- Stock Information
- Founded
- EGHT 1987
- CLLS 1999
- Country
- EGHT United States
- CLLS France
- Employees
- EGHT N/A
- CLLS N/A
- Industry
- EGHT EDP Services
- CLLS Biotechnology: Pharmaceutical Preparations
- Sector
- EGHT Technology
- CLLS Health Care
- Exchange
- EGHT Nasdaq
- CLLS Nasdaq
- Market Cap
- EGHT 250.2M
- CLLS 240.2M
- IPO Year
- EGHT 1997
- CLLS 2007
- Fundamental
- Price
- EGHT $1.96
- CLLS $2.01
- Analyst Decision
- EGHT Buy
- CLLS Buy
- Analyst Count
- EGHT 6
- CLLS 2
- Target Price
- EGHT $2.83
- CLLS $8.00
- AVG Volume (30 Days)
- EGHT 842.1K
- CLLS 22.3K
- Earning Date
- EGHT 10-30-2024
- CLLS 11-04-2024
- Dividend Yield
- EGHT N/A
- CLLS N/A
- EPS Growth
- EGHT N/A
- CLLS N/A
- EPS
- EGHT N/A
- CLLS N/A
- Revenue
- EGHT $723,565,000.00
- CLLS $19,635,000.00
- Revenue This Year
- EGHT $0.85
- CLLS $271.02
- Revenue Next Year
- EGHT $2.15
- CLLS $33.48
- P/E Ratio
- EGHT N/A
- CLLS N/A
- Revenue Growth
- EGHT N/A
- CLLS N/A
- 52 Week Low
- EGHT $1.51
- CLLS $0.96
- 52 Week High
- EGHT $3.92
- CLLS $3.77
- Technical
- Relative Strength Index (RSI)
- EGHT 50.53
- CLLS 41.74
- Support Level
- EGHT $1.78
- CLLS $1.95
- Resistance Level
- EGHT $2.20
- CLLS $2.06
- Average True Range (ATR)
- EGHT 0.11
- CLLS 0.10
- MACD
- EGHT -0.00
- CLLS -0.01
- Stochastic Oscillator
- EGHT 42.86
- CLLS 33.33
About EGHT 8x8 Inc
8x8 Inc provides contact-center-as-a-service and unified-communications-as-a-service software applications to approximately 2.5 million users. The company's unified platform enables omnichannel communication to assist employees in communicating across voice, video, text, chat, and contact centers. The Company also generates revenue from sales of hardware and professional services, which are complementary to the delivery of its integrated technology platform.. Geographically, it derives a majority of revenue from the United States.
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC, product candidates in other therapeutic indications.